NCT06653296 - A Dose-Response Safety Study of ENX-102 in Patients With GAD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

June 23, 2025

Study Completion Date

June 23, 2025

Conditions

General Anxiety Disorder

Interventions

DRUG

ENX-102

Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period

DRUG

Placebo

Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period

Trial Locations (3)

Unknown

MAC Clinical Research, Liverpool

MAC Clinical Research, Blackpool

MAC Clinical Research, Manchester